Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 16 peer-reviewed journal articles Updated
Neurology · Behavioral Variant Frontotemporal Dementia

Progression and End-of-Life Care

At a Glance

Behavioral variant frontotemporal dementia (bvFTD) is a progressive disease with an average timeline of 7 to 13 years from the first symptoms. In late stages, behavioral issues are often replaced by severe apathy, loss of speech, motor problems, and swallowing difficulties, making palliative care essential.

Understanding the road ahead with behavioral variant frontotemporal dementia (bvFTD) is one of the most difficult parts of the journey. Because the disease is progressive and life-limiting, the focus eventually shifts from managing behavioral symptoms to ensuring physical comfort and dignity [1]. While every person’s trajectory is unique, the disease typically follows a pattern of steady decline spanning several years [2].

Staging the Disease

Standard dementia tests often fail to capture the severity of bvFTD because they focus heavily on memory. To get a more accurate picture, doctors use a specialized tool called the CDR plus NACC FTLD (Clinical Dementia Rating plus National Alzheimer’s Coordinating Center Frontotemporal Lobar Degeneration) [3][4].

This scale evaluates eight different areas of life, including the six standard domains (like orientation and memory) plus two domains specific to FTD:

  1. Behavior, Comportment, and Personality (BEHAV): Tracks changes in social conduct, empathy, and impulsivity [3].
  2. Language (LANG): Measures the ability to communicate effectively [3].

By tracking the “Sum of Boxes” (the total score across these eight areas), the medical team can monitor how quickly the disease is progressing and adjust the care plan accordingly [5][6].

What to Expect in the Later Stages

As the disease reaches its more advanced stages, the highly disruptive behavioral symptoms may actually lessen as a deep apathy (total lack of initiative) takes over [7]. New challenges often emerge as the brain damage spreads:

  • Motor Symptoms: Many develop parkinsonism, which includes muscle stiffness, tremors, and a higher risk of falls [8][9]. If the disease overlaps with motor neuron disease (like ALS), there may be muscle twitching or profound limb weakness [10].
  • Loss of Speech: The person may become increasingly quiet, eventually leading to mutism, where they no longer speak at all [3].
  • Swallowing Difficulties (Dysphagia): In the final stages, the brain loses the ability to coordinate swallowing correctly [11]. This is a critical stage, as it increases the risk of aspiration pneumonia—when food or liquid enters the lungs instead of the stomach—which is a frequent cause of death in FTD [12][13].

Timeline and Trajectory

On average, the time from the first symptoms to the end of life is roughly 7 to 13 years, though this varies significantly based on the underlying genetics and the age at which symptoms began [2][14].

  • Fast vs. Slow Progressors: Some genetic forms, such as those involving the C9orf72 mutation (especially when paired with ALS), may progress more rapidly [10][15].
  • The Diagnosis Gap: Because it takes an average of 3 years just to get a correct diagnosis, many families find they are already “mid-way” through the disease by the time they have a name for it [2].

Focusing on Quality of Life

As the disease progresses, the family’s role will evolve into advocating for comfort. This is the time to lean on palliative care specialists—experts who focus on relieving symptoms and stress for both the patient and the caregiver. While the trajectory of bvFTD is a steady decline, the focus can remain on providing a environment that is safe, calm, and filled with the presence of those who love them [16].

Return to Home Page

Common questions in this guide

What is the life expectancy for someone with behavioral variant FTD?
On average, the time from the first symptoms to the end of life is roughly 7 to 13 years. This timeline can vary significantly depending on the age symptoms begin and underlying genetics, such as the C9orf72 mutation.
What are the symptoms of end-stage bvFTD?
In advanced stages, disruptive behavioral symptoms often lessen as deep apathy takes over. Patients may also develop motor symptoms like muscle stiffness, severe limb weakness, complete loss of speech, and difficulty swallowing.
How do doctors track the progression of bvFTD?
Doctors use a specialized tool called the CDR plus NACC FTLD scale. Unlike standard dementia tests that focus mostly on memory, this tool tracks changes in behavior, personality, social conduct, and language skills to give a more accurate picture of disease progression.
Why is difficulty swallowing a major concern in later stages?
As the disease progresses, the brain loses the ability to coordinate swallowing correctly. This increases the risk of aspiration pneumonia—a condition where food or liquid enters the lungs instead of the stomach—which is a frequent cause of death in advanced FTD.
When should we start thinking about palliative care?
It is helpful to involve palliative care specialists as the disease advances to focus on comfort and quality of life. They can help manage late-stage symptoms, reduce stress for the patient and caregiver, and support end-of-life planning.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What is the current score on the CDR plus NACC FTLD scale, and how should we expect that to change over the next year?
  2. 2.Are we seeing any signs of motor neuron involvement or ALS, and how would that change the speed of progression?
  3. 3.When should we begin having conversations about palliative care or hospice to ensure quality of life in the later stages?
  4. 4.How can we screen for swallowing difficulties (dysphagia) at home to prevent aspiration pneumonia?
  5. 5.What specialized resources are available for the 'end stage' of FTD, which can look different from other types of dementia?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (16)
  1. 1

    Understanding Frontotemporal Disease Progression and Management Strategies.

    Mulkey M

    The Nursing clinics of North America 2019; (54(3)):437-448 doi:10.1016/j.cnur.2019.04.011.

    PMID: 31331629
  2. 2

    Neuroimaging in Frontotemporal Dementia: Heterogeneity and Relationships with Underlying Neuropathology.

    Peet BT, Spina S, Mundada N, La Joie R

    Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics 2021; (18(2)):728-752 doi:10.1007/s13311-021-01101-x.

    PMID: 34389969
  3. 3

    Use of the CDR® plus NACC FTLD in mild FTLD: Data from the ARTFL/LEFFTDS consortium.

    Miyagawa T, Brushaber D, Syrjanen J, et al.

    Alzheimer's & dementia : the journal of the Alzheimer's Association 2020; (16(1)):79-90 doi:10.1016/j.jalz.2019.05.013.

    PMID: 31477517
  4. 4

    Utility of the global CDR® plus NACC FTLD rating and development of scoring rules: Data from the ARTFL/LEFFTDS Consortium.

    Miyagawa T, Brushaber D, Syrjanen J, et al.

    Alzheimer's & dementia : the journal of the Alzheimer's Association 2020; (16(1)):106-117 doi:10.1002/alz.12033.

    PMID: 31914218
  5. 5

    Utility of the Japanese version of the Clinical Dementia Rating® plus National Alzheimer's Coordinating Centre Behaviour and Language Domains for sporadic cases of frontotemporal dementia in Japan.

    Taomoto D, Sato S, Kanemoto H, et al.

    Psychogeriatrics : the official journal of the Japanese Psychogeriatric Society 2024; (24(2)):281-294 doi:10.1111/psyg.13072.

    PMID: 38152057
  6. 6

    Comparison of clinical rating scales in genetic frontotemporal dementia within the GENFI cohort.

    Peakman G, Russell LL, Convery RS, et al.

    Journal of neurology, neurosurgery, and psychiatry 2022; (93(2)):158-168 doi:10.1136/jnnp-2021-326868.

    PMID: 34353857
  7. 7

    Distinct early symptoms in neuropathologically proven frontotemporal lobar degeneration.

    Kawakami I, Arai T, Shinagawa S, et al.

    International journal of geriatric psychiatry 2021; (36(1)):38-45 doi:10.1002/gps.5387.

    PMID: 32748432
  8. 8

    Parkinsonism in frontotemporal dementias.

    Rowe JB

    International review of neurobiology 2019; (149()):249-275 doi:10.1016/bs.irn.2019.10.012.

    PMID: 31779815
  9. 9

    A Clinicopathologic Study of Movement Disorders in Frontotemporal Lobar Degeneration.

    de Pablo-Fernández E, González-Herrero B, Cerdán Santacruz D, et al.

    Movement disorders : official journal of the Movement Disorder Society 2021; (36(3)):632-641 doi:10.1002/mds.28356.

    PMID: 33155746
  10. 10

    Survival and Prognostic Factors in C9orf72 Repeat Expansion Carriers: A Systematic Review and Meta-analysis.

    Glasmacher SA, Wong C, Pearson IE, Pal S

    JAMA neurology 2020; (77(3)):367-376 doi:10.1001/jamaneurol.2019.3924.

    PMID: 31738367
  11. 11

    Motor involvement in frontotemporal lobar degeneration with TAR DNA-binding protein of 43 kDa type C.

    Yamashita R, Beck G, Shigenobu K, et al.

    Neuropathology : official journal of the Japanese Society of Neuropathology 2025; (45(4)):e13026 doi:10.1111/neup.13026.

    PMID: 39809580
  12. 12

    Aspiration Pneumonia.

    Pan D, Chung S, Nielsen E, Niederman MS

    Seminars in respiratory and critical care medicine 2024; (45(2)):237-245 doi:10.1055/s-0043-1777772.

    PMID: 38211629
  13. 13

    Pneumonitis and pneumonia after aspiration.

    Son YG, Shin J, Ryu HG

    Journal of dental anesthesia and pain medicine 2017; (17(1)):1-12 doi:10.17245/jdapm.2017.17.1.1.

    PMID: 28879323
  14. 14

    Time to diagnosis in younger-onset dementia and the impact of a specialist diagnostic service.

    Loi SM, Goh AMY, Mocellin R, et al.

    International psychogeriatrics 2022; (34(4)):367-375 doi:10.1017/S1041610220001489.

    PMID: 32854788
  15. 15

    Quantifying multimodal longitudinal brain changes in presymptomatic C9orf72 disease.

    Saracino D, Cipriano L, Houot M, et al.

    Alzheimer's & dementia : the journal of the Alzheimer's Association 2025; (21(12)):e70902 doi:10.1002/alz.70902.

    PMID: 41366786
  16. 16

    The tailored activity program (TAP) to address behavioral disturbances in frontotemporal dementia: a feasibility and pilot study.

    O'Connor CM, Clemson L, Brodaty H, et al.

    Disability and rehabilitation 2019; (41(3)):299-310 doi:10.1080/09638288.2017.1387614.

    PMID: 29034719

This page is for informational purposes only and does not replace professional medical advice. Always consult your neurology and palliative care teams regarding disease progression, prognosis, and end-of-life planning.

Get notified when new evidence is published on Behavioral variant of frontotemporal dementia.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.